Adverse Drug Events (ADEs) annually account for more than 1 million emergency department visits, 2.2 million hospital admissions, 3.5 million physician office visits, and $136 billion in U.S. health care costs. In addition to being the #1 most costly hospital-acquired condition, ADEs are also the #1 most preventable.
With pharmacogenomic testing (PGx), healthcare providers can better serve their patients by considering each of their patients’ genetic makeup when making prescribing decisions. In turn, the frequency of ADEs are reduced. However, the practice of precision medicine is not yet as common and widespread as it should be.
For this reason, the “Right Drug Dose Now Act” has been introduced by Representatives Emmer and Swalwell to increase awareness of ADEs, improve EHR systems, and provide funding in order to widely implement PGx testing. Ultimately, this leads to better overall patient outcomes.
At GenXys, we have been advocates for pharmacogenomic testing from the start. Our precision prescribing software eliminates “trial and error” prescribing and makes it easier for healthcare providers to provide tailored treatment to their patients. We are passionate about our mission of increasing medication safety and improving treatment responses, and we would like to spread the word about the importance of PGx testing. Join us on Wednesday, April 13th, 2022, at 11am PT/2pm ET for our upcoming webinar The RIGHT Act: Is this the catalyst for universal precision medicine through precision prescribing?
In this exclusive webinar, you will hear from Representative Emmer, Representative Swalwell, and a panel of PGx advocates fighting for policy change and legislation supporting better health outcomes. You will not want to miss out on this important conversation that will change the way you think about precision medicine and the healthcare system.
Register now, here!